TITLE:
Study of CEP-701 in Treatment of Prostate Cancer

CONDITION:
Prostate Cancer

INTERVENTION:
CEP-701

SUMMARY:

      The purpose of this study is to determine the proportion of patients with a serological
      prostate specific antigen (PSA) by day 85.
    

DETAILED DESCRIPTION:

      A serological PSA response is defined as a reduction from baseline PSA serum concentration
      of at least 50%, which is confirmed by a second PSA value 28 or more days later.
    

ELIGIBILITY:
Gender: Male
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  at least 18 yrs of age

          -  diagnosis of adenocarcinoma of the prostate

          -  no detectable metastatic disease as assessed by bone and CT scans

          -  has increasing serum PSA concentrations

          -  life expectancy of at least 3 months

          -  ECOG of 0 or 1

          -  has been withdrawn from antiandrogen therapy for at least 6 weeks prior to entering
             screening period

        Exclusion Criteria:

          -  has asymptomatic disease

          -  has active GI ulceration or bleeding

          -  has been treated with non-hormonal systemic anticancer therapy or has received
             radiation within 4 weeks of baseline visit

          -  bilirubin >2x ULN or ALT or AST >2xULN or serum creatinine >1.5mg/dL

          -  hemoglobin <9g/dL or platelets below 100,000/uL or ANC below 1500/uL

          -  receiving treatment for HIV with protease inhibitors

          -  has had prior malignancy within past 5 yrs with exception of resected basal or
             squamous cell carcinomas of the skin

          -  has used investigational drug with previous one month
      
